



Consiglio Nazionale delle Ricerche

Istituto Scienze dell'Alimentazione

Institute of Food Sciences

RELAZIONE SCIENTIFICA SHORT TERM MOBILITY

Dall'01/03/2018 al 22/01/2018

Proponente/Fruitore: Gian Luigi Russo

Istituto di afferenza del Fruitore: Istituto Scienze dell'Alimentazione, CNR

Programma di ricerca svolto Composti fenolici inibitori delle fosfatasi Sts-1 e Sts-2

Istituzione ospitante: School of Medicine, Department of Molecular Genetics and Microbiology, Stony Brook State University of New York, New York, USA

Ricercatore Ospitante: dr. Nicholas Carpino

Il gruppo del Dr. Carpino è leader nello studio della del T-cell receptor (TCR) la cui attivazione/deattivazione regola la risposta immunitaria. Il dr. Carpino ha descritto per primo nel 2009 una nuova regolazione del TCR ad opera di fosfatasi che agirebbero a livello della chinasi ZAP-70 (Mol Immunol. 2009; 46:3224-31). Le due fosfatasi coinvolte in tale processo sono Sts-1 and Sts-2 (Suppressor of TCR Signaling) appartenenti a una famiglia di proteine caratterizzata da una struttura tripartita unica composta da una regione N-terminale UBA che lega l'ubiquitina, un dominio centrale SH3 (*Src* omologia 3) per l'interazioni proteina-proteina, e un dominio PGM (fosfoglicerato mutasi) C-terminale trovato in un gruppo di enzimi strutturalmente correlati che sono noti agire come fosfatasi o phosphotransferasi. Il gruppo del dr. Carpino ha dimostrato che entrambe le fosfatasi sono in grado di defosforilare residui di tirosina che regolano l'attività chinastica di ZAP-70. Inoltre, linfociti-T periferici isolati da topi ingegnerizzati per mancanza di entrambe le fosfatasi Sts-1 e Sts-2 (Sts-1/2^{-/-}) mostrano aumentata fosforilazione di ZAP-70 con conseguente iper-stimolazione del TCR, a conferma del ruolo di regolatore negativo di Sts-1 e Sts-2 nelle vie di trasduzione del segnale dipendenti dal TCR (Immunity 2004; 20:37–46; Mol. Cell 2007; 27:486–497).

Più di recente lo stesso gruppo di ricerca ha dimostrato che l'inattivazione funzionale di entrambi gli enzimi Sts-1/2 causa una significativa resistenza all' infezioni sistemiche da *Candida albicans*, con più del 80% di topi privi di *STS-1* e -2 che mostravano una sopravvivenza a una dose di *C. albicans* ($2,5 \times 10^5$ CFU / topo) normalmente letale per topi wild-type entro 10 giorni (Infect Immun. 2015; 83:637-45; Front Cell Infect Microbiol. 2017;7:481).

Il gruppo di ricerca presso l'ISA-CNR di Avellino diretto dal Fruitore della presente STM si occupa da tempo del ruolo di molecole naturali nella terapia di forme leucemiche resistenti alla chemioterapia tradizionale (Food Funct. 2014;5:2393-401; Ann N Y Acad Sci. 2012;1259:95-103). Lo stesso gruppo ha dimostrato che la quercetina, un flavonoide largamente presente in frutta, verdura ed alcune bevande, è capace di migliorare l'effetto terapeutico di farmaci chemioterapici in un modello sperimentale rappresentato da cellule B isolate da pazienti affetti da leucemia linfocitica cronica (CLL) (British J Cancer 2010; 103:642-648; British J Cancer 2011; 105:221-30; Biochem Pharmacol. 2013;85:927-36; Oncotarget. 2017;8:42571-42587). Inoltre, dati di letteratura indicano che alcuni polifenoli quali genisteina e EGCG sono in grado di modulare l'attività chinastica di ZAP-70 nelle CLL

(Cancer Immunol Immunother 2007; 56:501–514; J. Biol. Chem. 2008; 283: 28370–9), per cui, paradossalmente, flavonoidi naturali potrebbero risultare più efficaci nel trattamento di CLL più aggressive che presentano elevati livelli di ZAP-70. Questa condizione potrebbe essere favorita da inibitori di Sts-1/2. Per quanto sopra detto, la ricerca di inibitori di Sts-1 e Sts-2 potrebbe trovare risvolti applicativi sia nella cura da infezioni da *C. albicans* che nelle terapie della CLL.

La collaborazione in itinere tra i due gruppi di ricerca ha permesso di evidenziare che estratti arricchiti in polifenoli da diversi alimenti (olio, vino rosso, tè verde, mela, cioccolato, cipolla rossa, melograno, ecc.) preparati presso l'ISA-CNR-Avellino erano in grado di inibire l'attività delle fosfatasi Sts-1 e Sts-2, utilizzando come fonte di attività enzimatica i rispettivi domini PGM (*phosphoglycerate mutase-like domain*) espressi e purificati in *E. coli* (si veda relazione finale STM 2015). Tali risultati sono riassunti in **Fig. 1**.




Fig. 1. Saggi *in vitro* di attività enzimatica per Sts-1 (pannello A) e Sts-2 (pannello B) in cui si è misurata la capacità di vari estratti polifenolici di inibire l'attività delle due fosfatasi. Vino rosso (Extract-1); Melograno (Extract-2); Cipolla (Extract-3); Cacao (Extract-4); Fejoia (Extract-5); Sambuco (Extract-6); Birra (Extract-7); Capperi (Extract-8); Olio d'oliva (Extract-9); Tè verde (Extract-10).

In seguito alla recente pubblicazione del gruppo del Dr. Carpino del clonaggio ed espressione in *E. coli* della proteina Sts-1 umana *full-length* (Sts-1_{FL}) (Biochemistry. 2017;56:4637-4645), si è deciso di verificare, come riportato tra gli obiettivi della presente STM, se anche la forma Sts-1_{FL} fosse in grado di essere inibita da alcuni degli estratti indicati in Fig. 1 e/o da frazioni semi-pure da essi derivate e rappresentanti diverse classi di composti fenolici.

I saggi di attività fosfatasica sono stati eseguiti come descritto (J. Biol. Chem. 2011; 286: 15943–15954; Molecular Cell 2007; 27:486–497) utilizzando il PNPP (p-nitrofenil fosfato; assorbanza a 405 nm) come substrato per Sts-1.




Fig. 2. Saggi *in vitro* di attività enzimatica per Sts-1_{FL} in cui si è misurata la capacità degli estratti polifenolici indicati di inibire l'attività dell'enzima.

Come si evince dai valori di percentuale di inibizione, gli estratti selezionati inibiscono Sts-1_{FL} in maniera confrontabile a quanto avveniva con il solo dominio PGM (Fig. 1). Dal confronto tra i due saggi, appare che, ad eccezione, del tè verde, gli altri estratti mostravano una maggiore efficacia inibitoria nei confronti del *full lenght* rispetto al dominio fosfatasico.





Fig. 3. Saggi *in vitro* di attività enzimatica per Sts-1_{FL} in cui si è misurata la capacità di quercetina, rutina e resveratrolo (RSV) di inibire l'attività dell'enzima.

Utilizzando molecole pure, note per la loro attività biologica e generalmente presenti negli estratti polifenolici (e.g. resveratrolo e quercetina con il suo glucoside rutina) a concentrazioni relativamente alte (500 μ M) rispetto a quelle presenti negli estratti di partenza, si è misurata una ridotta inibizione enzimatica (Fig. 3). Ciò suggerisce che probabilmente l'effetto inibitorio mostrato in Fig.2 non è imputabile a tali composti.

L'estratto di melograno, di cui si possedevano frazioni ulteriormente purificate utilizzando il metodo descritto da Sun et al. (J. Chromatography A, 2006; 1128:27–38), è stato impiegato per ulteriori analisi.



SEP-PAK C18 SEPARATION POMEGRANADE

Fig. 4. Saggi in vitro di attività enzimatica per Sts-1_{FL} su frazioni fenoliche ottenute dall'estratto di vino rosso dopo purificazione su Sep-Pak utilizzando il metodo descritto da Sun et al., 2006.

Come mostrato in Fig. 4, la frazione eluita con 50% metanolo coincideva con la maggiore attività inibitoria.

In conclusione, questa parte di lavoro eseguito nel corso della presente STM ha confermato che la capacità degli estratti polifenolici di inibire l'attività del dominio fosfatase di STS-1 è conservata anche nell'enzima *full lenght*. Ulteriori studi sono necessari per isolare e caratterizzare le singole molecole responsabili dell'attività inibitoria presenti negli estratti utilizzati. I dati qui riassunti, insieme ad altri accumulati nel corso della collaborazione in itinere saranno oggetto di un *research paper* in corso di scrittura.

Nel corso della presente STM, il responsabile dell'istituzione ospitante, dr. Carpino, ha invitato il Proponente a dare il proprio contributo per completare le attività sperimentali di un lavoro nella fase finale di preparazione. L'argomento, strettamente inerente l'oggetto della STM, riguarda il meccanismo d'azione responsabile della risposta all'infezione da *C. albicans* da parte di fagociti murini con delezione dei geni Sts (double knock-out per i geni STS₂, dKO-Sts^{-/-}). La pathway di riferimento, illustrata nella Fig. 5 sottostante (Front Cell Infect

Microbiol. 2017;7:481), suggerisce il coinvolgimento della proteina chinasi Syk e delle sue diverse isoforme.




Fig. 5. La perdita di funzione delle proteine Sts può promuovere la resistenza alle infezioni da *C. albicans*. In *T-cells*, Sts-1 e -2 inibiscono l'attivazione della chinasi Zap-70 a livello del TCR. Syk è un omologo di Zap-70 espresso in fagociti. Ciò suggerisce che le proteine Sts potrebbero regolare negativamente l'attività di Syk (da Front Cell Infect Microbiol. 2017;7:481).

Il Proponente ha eseguito una serie di immunoblotting, riassunti nella successiva Fig. 6 da cui è risultato che in cellule dendritiche isolate da topi *single KO* per Sts-1 e Sts-2 o *double KO* dopo stimolazione con zymosan che mima l'infezione da *C. albicans*. L'aumentata espressione di entrambe le forme fosforilate ed attive di Syk (Tyr352 e Tyr525/526) si osservava solo in topi KOSTs-1 e dKOSTs rispetto agli animali WT, suggerendo un ruolo primario di Sts-1 nell'inibizione di Syk.



ANTIBODY		LEGENDS	NOTES-1
(p)Syk Tyr352		From left to right: WT (0-10-20 min) Sts-1-KO (0-10-20 min) dKO (0-10-20 min) Sts-2-KO (0-10-20 min)	<p>-Increase expression of p-SYK(Y352) only in Sts-1-KO compared to WT after stimulation.</p> <p>Unphosphorylated SYK co-migrate with abundantly expressed proteins running at similar MW which may confound its separation from the phospho-forms</p>
(p)Syk Tyr525/526		From left to right: WT (0-10-20 min) Sts-1-KO (0-10-20 min) Sts-2-KO (0-10-20 min) dKO (0-10-20 min)	<p>-Increase expression of p-SYK(Y526) only in Sts-1-KO compared to WT after stimulation.</p>

Fig. 6. Immunoblots esemplificativi che mostrano l'attivazione delle diverse isoforme fosforilate di Syk (Tyr352 e Tyr525/526) solo nelle cellule dendritiche derivanti da topi *single KO* per Sts-1 e *double KO* per Sts-1 e Sts-2..



Consiglio Nazionale delle Ricerche

Istituto Scienze dell'Alimentazione

Institute of Food Sciences

I dati riportati sono stati oggetto di una recentissima pubblicazione (dal titolo "*Phagocytes from mice lacking the Sts phosphatases have an enhanced anti-fungal response to C. albicans.*" di cui il Proponente è co-autore.

L'articolo è allegato alla presente relazione e riporta a pag. 12 i "ringraziamenti" all'Ente.

Per tutto quanto non riportato nella presente relazione, il Proponente è disponibile a fornire ulteriori informazioni.

In fede,
Gian Luigi Russo
Fruitore STM



Phagocytes from Mice Lacking the Sts Phosphatases Have an Enhanced Antifungal Response to *Candida albicans*

David Frank,^{a,b} Shamoon Naseem,^b Gian Luigi Russo,^{b,c} Cindy Li,^b Kaustubh Parashar,^b James B. Konopka,^b  Nick Carpino^{a,b}

^aProgram in Molecular and Cellular Pharmacology, Stony Brook University, Stony Brook, New York, USA

^bDepartment of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York, USA

^cInstitute of Food Sciences, National Research Council, Avellino, Italy

ABSTRACT Mice lacking expression of the homologous phosphatases Sts-1 and Sts-2 (Sts^{-/-} mice) are resistant to disseminated candidiasis caused by the fungal pathogen *Candida albicans*. To better understand the immunological mechanisms underlying the enhanced resistance of Sts^{-/-} mice, we examined the kinetics of fungal clearance at early time points. In contrast to the rapid *C. albicans* growth seen in normal kidneys during the first 24 h postinfection, we observed a reduction in kidney fungal CFU within Sts^{-/-} mice beginning at 12 to 18 h postinfection. This corresponds to the time period when large numbers of innate leukocytes enter the renal environment to counter the infection. Because phagocytes of the innate immune system are important for host protection against pathogenic fungi, we evaluated responses of bone marrow leukocytes. Relative to wild-type cells, Sts^{-/-} marrow monocytes and bone marrow-derived dendritic cells (BMDCs) displayed a heightened ability to inhibit *C. albicans* growth *ex vivo*. This correlated with significantly enhanced production of reactive oxygen species (ROS) by Sts^{-/-} BMDCs downstream of Dectin-1, a C-type lectin receptor that plays a critical role in stimulating host responses to fungi. We observed no visible differences in the responses of other antifungal effector pathways, including cytokine production and inflammasome activation, despite enhanced activation of the Syk tyrosine kinase downstream of Dectin-1 in Sts^{-/-} cells. Our results highlight a novel mechanism regulating the immune response to fungal infections. Further understanding of this regulatory pathway could aid the development of therapeutic approaches to enhance protection against invasive candidiasis.

IMPORTANCE Systemic candidiasis caused by fungal *Candida* species is becoming an increasingly serious medical problem for which current treatment is inadequate. Recently, the Sts phosphatases were established as key regulators of the host antifungal immune response. In particular, genetic inactivation of Sts significantly enhanced survival of mice infected intravenously with *Candida albicans*. The Sts^{-/-} *in vivo* resistance phenotype is associated with reduced fungal burden and an absence of inflammatory lesions. To understand the underlying mechanisms, we studied phagocyte responses. Here, we demonstrate that Sts^{-/-} phagocytes have heightened responsiveness to *C. albicans* challenge relative to wild-type cells. Our data indicate the Sts proteins negatively regulate phagocyte activation via regulating selective elements of the Dectin-1–Syk tyrosine kinase signaling axis. These results suggest that phagocytes lacking Sts respond to fungal challenge more effectively and that this enhanced responsiveness partially underlies the profound resistance of Sts^{-/-} mice to systemic fungal challenge.

KEYWORDS *Candida albicans*, cell signaling, effector functions, host-pathogen interactions, innate immunity

Received 10 April 2018 Accepted 20 June 2018 Published 17 July 2018

Citation Frank D, Naseem S, Russo GL, Li C, Parashar K, Konopka JB, Carpino N. 2018. Phagocytes from mice lacking the Sts phosphatases have an enhanced antifungal response to *Candida albicans*. mBio 9:e00782-18. <https://doi.org/10.1128/mBio.00782-18>.

Invited Editor Bruce Steven Klein, University of Wisconsin—Madison

Editor J. Andrew Alspaugh, Duke University Medical Center

Copyright © 2018 Frank et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Nick Carpino, nicholas.carpino@stonybrook.edu.

In recent years, an increase in the numbers of invasive infections by fungal pathogens has raised concern (1). Of particular clinical concern are diverse *Candida* species, including *Candida albicans*. *C. albicans* is responsible for a number of infectious disorders, including oral candidiasis, chronic mucocutaneous candidiasis, and invasive candidiasis, a potentially lethal infection in which the fungus disseminates systemically and proliferates within internal tissues (2). *C. albicans* accounts for over 50,000 hospital-acquired systemic infections in the United States alone, with a 30% to 40% mortality rate associated with the invasive form of the disease (3, 4). Current antifungal medications used to treat systemic *C. albicans* infections have a number of drawbacks, including high cost, toxicity, and difficulties achieving appropriate bioavailability within infected tissues (1, 5). These limitations are compounded by difficulties in making a rapid and accurate disease diagnosis (6). In addition, the emergence of drug-resistant *Candida* strains is now considered a major threat by the CDC (7, 8).

Phagocytes of the innate immune system play a critical role in the immune response to *C. albicans* (9). Fungal cell wall constituents are recognized by cell-surface Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), promoting the activation of cellular antimicrobial effector pathways (10). However, excessive inflammatory responses that occur in the context of fungal infections can also be counterproductive and lead to detrimental collateral tissue damage (11, 12). For example, in a mouse model of systemic candidiasis, progressive sepsis caused by a vigorous inflammatory response has been identified as the cause of death (13). In this context, it has been observed that reducing inflammation by reducing levels of proinflammatory factors can lead to improved host survival (14, 15). Optimizing clinical outcomes to *C. albicans* infection will require a more complete understanding of the biochemical mechanisms that underlie leukocyte antifungal inflammatory responses.

We recently reported that two homologous phosphatases, Sts-1 and Sts-2, play key roles in regulating the host response to systemic *C. albicans* infection (16). The Sts enzymes share overlapping and redundant functions as negative regulators of hematopoietic signaling pathways (17–19). They have a distinctive structure consisting of two protein interaction domains (UBA and SH3) and a C-terminal 2H-phosphatase domain that is structurally and enzymatically very distinct from those of other intracellular protein phosphatases known to regulate immune signaling pathways (20). Within hematopoietic cell populations, Sts-1 has been shown to negatively regulate signaling downstream of the TCR by targeting the Zap-70 kinase (17) and both GPVI-FcR γ signaling in platelets and Fc ϵ RI signaling in mast cells by targeting the Zap-70 homologue Syk (21, 22).

Sts^{−/−} mice are profoundly resistant to disseminated candidiasis caused by supralethal inoculums, displaying significantly enhanced survival and an ability to clear the infection (16). To define the mechanisms underlying the enhanced resistance of Sts^{−/−} mice, we investigated the role of Sts^{−/−} leukocytes. Our results demonstrate that bone marrow-derived dendritic cells (BMDCs) lacking Sts expression have an enhanced ability to inhibit *C. albicans* growth and may contribute significantly to the resistance of Sts^{−/−} mice. Further, we demonstrate that, within BMDCs, the Sts phosphatases negatively regulate the activation of select pathways downstream of the key fungal pathogen pattern recognition receptor Dectin-1. These observations define a novel role for Sts in regulating host antimicrobial effector responses and provide mechanistic insights into the ability of Sts^{−/−} mice to resist lethal systemic *C. albicans* infection.

RESULTS

Inhibition of *C. albicans* growth within 24 h in Sts^{−/−} mice. In the mouse model of invasive candidiasis, the kidneys are the predominant niche for *C. albicans* proliferation (23). Fungal germination is evident within 2 h postinfection, and kidney fungal CFU levels increase by 2 orders of magnitude over the course of 48 h (24, 25). Previous studies showed that Sts^{−/−} mice exhibit a significantly lower kidney fungal burden that is especially evident by 48 h postinfection (16). To determine more precisely when levels of wild-type and Sts^{−/−} kidney fungal CFU begin to diverge, we compared the




FIG 1 Reduced fungal CFU in *Sts*^{-/-} kidneys at early time points postinfection. Kidneys from mice infected with 2.5×10^5 CFU were assessed for fungal burden prior to 24 h. Results represent averages of 2 to 3 independent experiments each carried out with 5 to 6 mice per group. **, $P < 0.001$ (by Mann-Whitney analysis) (error bars = standard deviations [SD] of means). WT, wild type.

fungal loads in wild-type and *Sts*^{-/-} kidneys at early time points. Figure 1 illustrates that *C. albicans* within wild-type and *Sts*^{-/-} kidneys proliferates at similar levels in the first 12 h following infection. However, while fungal CFU levels continue to increase after 12 h in wild-type kidneys, they begin to decrease in *Sts*^{-/-} kidneys at between 12 and 18 h (Fig. 1). In this timeframe, similar numbers of leukocytes in wild-type and *Sts*^{-/-} mice have entered the kidneys (16). These data indicate that within 12 to 18 h postinfection, mice lacking the *Sts* proteins are more effective than wild-type mice at inhibiting fungal growth and eliminating *C. albicans* cells from the kidney.

Hematopoietic stem cell (HSC)-derived cells contribute to the enhanced resistance of *Sts*^{-/-} mice. Having established that enhanced kidney fungal restriction in *Sts*^{-/-} animals becomes evident during the time period when bone marrow leukocyte populations begin to enter the renal compartment, we next determined if *Sts*^{-/-} hematopoietic cells played a role. Transplantation of *Sts*^{-/-} donor marrow into irradiated wild-type or *Sts*^{-/-} recipients enhanced survival of *Candida* infection relative to the results seen with wild-type donor cells (Fig. 2A). Additionally, irradiated wild-type and *Sts*^{-/-} mice reconstituted with *Sts*^{-/-} bone marrow displayed a significant reduction in the 24-h fungal burden relative to mice receiving wild-type bone marrow (Fig. 2B). We also noted that *Sts*^{-/-} recipients displayed improved survival relative to wild-type recipients given equivalent amounts of donor marrow (Fig. 2A), suggesting that a nonhematopoietic component also contributes to the increased survival of *Sts*^{-/-} animals. To address whether phagocytic cells play a critical role in the *Sts*^{-/-} resistance phenotype, we evaluated the 24-h fungal burden in mice that had been administered the phagocyte-depleting agent clodronate 24 h prior to infection (26). As expected, clodronate treatment led to higher fungal burdens. Noticeably, however, it also eliminated the 24-h fungal clearance advantage normally associated with *Sts*^{-/-} animals (Fig. 2C). Together, these data suggest that the hematopoietic cell compartment makes an important contribution to the enhanced resistance of *Sts*^{-/-} mice.

Enhanced candidacidal activity of *Sts*^{-/-} leukocytes *ex vivo*. The regulatory role of the *Sts* proteins in innate leukocyte populations has not been explored. Both *Sts*-1 and *Sts*-2 are expressed by marrow cells at levels comparable to those within peripheral blood leukocytes and splenic cells (see Fig. S1A in the supplemental material). Therefore, we utilized an *in vitro* cell/fungal coculture assay to examine directly the interaction of bone marrow cells with fungal cells *ex vivo* (27). Marrow cells isolated from uninfected wild-type and *Sts*^{-/-} mice were placed in culture and incubated with *C. albicans* *cph1Δ efg1Δ* cells. The *cph1Δ efg1Δ* mutant was used because it fails to undergo hyphal growth (28), thereby facilitating accurate quantification of fungal growth. After 24 h, we recovered equivalent CFU levels in cocultures containing untreated wild-type or *Sts*^{-/-} marrow cells (Fig. 3A). In the presence of the immune cell activator phorbol myristate acetate (PMA), fewer fungal CFU were obtained (Fig. 3A). Significantly, PMA-treated *Sts*^{-/-} marrow cells were more efficient at inhibiting fungal growth than treated wild-type marrow cells (Fig. 3A). This suggests that the antifungal




FIG 2 Contribution of *Sts*^{-/-} hematopoietic stem cell (HSC)-derived cells to the heightened resistance of *Sts*^{-/-} mice. (A) Radiation chimeras were infected with *C. albicans* (2.5×10^5 CFU) by bloodstream inoculation and monitored for 28 days. Wild-type (top) or *Sts*^{-/-} (bottom) recipients receiving *Sts*^{-/-} marrow demonstrated significantly enhanced survival, as indicated. *, $P < 0.05$ (by log rank analysis). (B) Radiation chimeras were infected with *C. albicans* (2.5×10^5 CFU) by bloodstream inoculation, and kidney CFU levels at 24 h postinfection were evaluated. Wild-type (top) or *Sts*^{-/-} (bottom) recipients receiving *Sts*^{-/-} marrow demonstrated significantly reduced 24-h kidney fungal CFU levels relative to mice receiving wild-type marrow. **, $P < 0.01$ (by Mann-Whitney analysis) (error bars = SD of means). (C) Mice treated with control liposomes (–) or a clodronate/liposome formulation (+) were infected 24 h later with 10^5 *C. albicans* cells. *Sts*^{-/-} mice treated with clodronate failed to display enhanced fungal restriction in the kidney 24 h postinfection.




FIG 3 Increased antifungal activity of *Sts*^{-/-} phagocytes *ex vivo*. (A) Nonfilamentous *C. albicans* *cph1Δ efg1Δ* cells were cocultured with untreated or PMA-treated bone marrow cells, and fungal CFU levels were determined after 24 h. Representative results of 3 experiments performed in triplicate are displayed. (B to F) Purified (B) bone marrow monocytes, (C) bone marrow neutrophils, (D) *ex vivo*-derived BMDCs, (E) BMDMs, or (F) BMD monocytes were cultured for 24 h with fungal cells, and CFU levels were enumerated as described for panel A. Results depict the average CFU of 3 experiments performed in triplicate. **, $P < 0.01$; *, $P < 0.05$ (by Mann-Whitney analysis) (error bars = SD of means).

properties of PMA-treated bone marrow cells are potentiated in the absence of Sts expression.

Marrow cell types associated with the initial innate immune response to systemic *C. albicans* infection include neutrophils and monocytes (29–31). Sts-1 and Sts-2 were found to be highly expressed in both cell populations (Fig. S1B and C [for cell purity data, see Fig. S2]). In order to examine the role of Sts in the antifungal responses of bone marrow monocytes and neutrophils, cells were purified from preparations of murine marrow. Sts^{-/-} marrow monocytes exhibited 10-fold-greater inhibition of fungal growth than the corresponding wild-type cultures (Fig. 3B). As in the case of total bone marrow cell coculture, the increased fungal-growth-inhibitory properties displayed by Sts^{-/-} monocytes was evident only when cells were pretreated with PMA. In contrast to marrow monocytes, PMA-treated neutrophils lacking Sts expression were less efficient at inhibiting fungal growth than wild-type neutrophils, although both were better at inhibiting fungal growth than untreated cells (Fig. 3C). We also examined the different phagocyte populations that can be obtained by culturing bone marrow *ex vivo* in the presence of different cytokines. These include bone marrow-derived dendritic cells (BMDCs) (32), bone marrow-derived macrophages (BMDMs) (33), and bone marrow-derived monocytes (BMD monocytes) (34) (see Fig. S1D to F). Similarly to bone marrow cells and marrow monocytes, Sts^{-/-} BMDCs exhibited a significantly greater ability to restrict *C. albicans* growth *ex vivo* than wild-type BMDCs (Fig. 3D). In contrast, no differences were observed in the growth-inhibitory properties of wild-type and Sts^{-/-} BMDMs and BMD monocytes (Fig. 3E and F). Cumulatively, our results suggest that the Sts proteins play a negative role in regulating antifungal properties of select phagocyte populations.

Increased *Candida*-induced ROS production in cells lacking Sts expression.

Because Sts^{-/-} BMDCs displayed enhanced fungal growth suppression *ex vivo* (Fig. 3D), we next investigated their antifungal effector functions. Members of the C-type lectin receptor (CLR) superfamily, including Dectin-1, are among the surface receptors engaged by fungal cells (35, 36). We stimulated cells with zymosan, a crude preparation of yeast cell wall extract that engages antifungal TLRs and CLRs, and observed a significantly greater zymosan-induced reactive oxygen species (ROS) response in Sts^{-/-} BMDC cultures than in wild-type BMDCs. In particular, both the rate of ROS production and the peak ROS signal were significantly enhanced in cells lacking Sts (Fig. 4A, left). We then evaluated the ROS response of BMDCs treated with *C. albicans* cells. After addition of either live or heat-killed (HK) *C. albicans* to BMDC cultures, production of ROS became evident, although the onset of the ROS response was delayed relative to cells treated with zymosan (Fig. 4A, middle and right panels). Similarly to the response seen following zymosan treatment, ROS production by Sts^{-/-} BMDCs following challenge with fungal cells was significantly augmented relative to the ROS response of wild-type BMDCs. In contrast to BMDCs, wild-type and Sts^{-/-} neutrophils (Fig. 4B) and BMD monocytes (Fig. S3A) did not display any differences in fungus-induced ROS production, while BMDMs of both genotypes did not generate a fungus-induced ROS response (Fig. S3B). Stimulation of BMDCs with heat-killed *C. albicans* *cph1Δ efg1Δ* cells also produced a heightened ROS response in Sts^{-/-} cells relative to wild-type cells (Fig. S4). Together, our data indicate that the Sts proteins negatively regulate the activation of fungus-induced ROS production in BMDCs.

In addition to ROS production, fungus-stimulated phagocytes produce diverse proinflammatory cytokines, including tumor necrosis factor alpha (TNF- α), interleukin-6 (IL-6), and IL-1 β (37). In the case of the latter, activation of the NLRP3 inflammasome downstream of the fungal receptor Dectin-1 results in upregulation of IL-1 β secretion (38). In contrast to the differential ROS responses observed between wild-type and Sts^{-/-} BMDCs, we detected no differences in the production of TNF- α , IL-6, or IL-1 β by cells lacking Sts expression relative to wild-type cells (Fig. 4C to E). Additionally, wild-type and Sts^{-/-} cells upregulated Nos2 expression to similar extents following stimulation, resulting in identical levels of NO production (Fig. 4F and G). These results




FIG 4 Increased *Candida*-induced ROS production in *Sts*^{-/-} BMDCs. (A) Wild-type and *Sts*^{-/-} BMDCs were stimulated with zymosan, heat-killed (HK) *C. albicans*, or live *C. albicans* as indicated, and levels of ROS production were assessed by luminol chemiluminescence. Average results of at least three separate experiments each conducted in triplicate are displayed. *P* values for the areas under each curve were calculated by Mann-Whitney analysis. RLU, relative light units. (B) Wild-type and *Sts*^{-/-} neutrophils were stimulated as described for panel A and levels of ROS production assessed. (C) Equivalent levels of TNF- α in wild-type and *Sts*^{-/-} BMDC culture supernatants stimulated with zymosan or HK *C. albicans* for 24 h, as indicated. Combined results of at least three separate experiments each conducted in duplicate are displayed. (D) Equivalent levels of IL-6 in wild-type and *Sts*^{-/-} BMDC culture supernatants stimulated with zymosan or HK *C. albicans* for 24 h, as indicated. Representative (zymosan) or combined (HK *C. albicans*) results of at least three separate experiments each (Continued on next page)




FIG 5 Sts regulates ROS production downstream of fungal CLR Dectin-1. (A) Wild-type and *Sts*^{-/-} BMDCs were stimulated with particulate β -glucan, and then levels of ROS production were assessed by luminol chemiluminescence. (B) Zymosan-induced (left) or HK (heat-killed) wild-type *C. albicans*-induced (right) ROS production in wild-type and *Sts*^{-/-} BMDCs was assessed in the absence (-) or presence (+) of soluble β -glucan, a specific inhibitor that blocks activation of Dectin-1 signaling pathways (46). (C) ROS production in wild-type and *Sts*^{-/-} BMDCs was assessed in the absence (-) or presence (+) of a blocking anti-Dectin-1 antibody. (D) Equivalent levels of surface Dectin-1 receptor expressed on wild-type BMDCs (solid red line) and *Sts*^{-/-} BMDCs (dotted dark blue line), evaluated by flow cytometry with a specific anti-Dectin-1 antibody. Nonshaded lines represent a nonspecific rat IgG control. (E) Equivalent levels of zymosan stimulation-dependent downregulation of surface Dectin-1 on wild-type (closed dot) and *Sts*^{-/-} (open dot) BMDCs. MFI, mean fluorescence intensity. For panels A to C, average values from at least 3 independent experiments each performed in triplicate are presented. *P* values were calculated by Mann-Whitney analysis.

suggest that the Sts proteins regulate a subset of phagocyte antifungal effector functions that includes the production of reactive oxygen species.

Sts regulates ROS production downstream of fungal receptor Dectin-1. Dectin-1 is a CLR that is stimulated by *C. albicans* and mediates activation of numerous downstream pathways (39, 40). Among the ligands that stimulate Dectin-1 are polymeric forms of β -glucan that are components of fungal cell walls (10). To investigate the involvement of Dectin-1, we treated BMDCs with purified particulate β -1,3 glucan polymers and found that *Sts*^{-/-} BMDCs demonstrated significantly increased ROS production relative to wild-type cells (Fig. 5A). Unlike polymeric β -glucan, soluble monomeric β -glucan acts in a competitive inhibitory fashion and blocks access to the Dectin-1 ligand-binding surface (41). After addition of soluble β -glucan to BMDC cocultures, the enhanced ROS response of *Sts*^{-/-} cells following zymosan or HK *C. albicans* stimulation was inhibited (Fig. 5B). The elevated ROS response of *Sts*^{-/-} BMDCs was also abrogated following addition of a blocking anti-Dectin-1 antibody to cocultures but not following addition of a control antibody (Fig. 5C). Importantly, we noted no difference in levels of surface expression of Dectin-1 on wild-type and *Sts*^{-/-} BMDCs (Fig. 5D). Similarly, no differences in the stimulation-dependent downregulation of Dectin-1 from the cell surface were observed (Fig. 5E). These results suggest that the

FIG 4 Legend (Continued)

conducted in duplicate are displayed. (E) Equivalent levels of IL-1 β in wild-type and *Sts*^{-/-} BMDC culture supernatants stimulated for 24 h with 100 μ g/ml zymosan. (F) Equivalent levels of nitrite, representative of NO production, in wild-type and *Sts*^{-/-} BMDC culture supernatants stimulated with zymosan (left) or HK *C. albicans* (right) for 24 h. Combined results of at least three separate experiments each conducted in duplicate are displayed. (G) Induction of Nos2 in zymosan-stimulated BMDCs. Representative results of two separate experiments are displayed. (Error bars for panels C to F = SD of means).




FIG 6 Increased activation of Syk and PLCγ2 downstream of Dectin-1. Wild-type or *Sts*^{-/-} BMDCs were stimulated with either zymosan or live *C. albicans* (MOI of 0.5) for the indicated times, and levels of activation of (A) Src kinases; (B) Shp2 phosphatase; (C) Syk; (D) PLCγ2; (E) ERK1/2; (F) Akt; and (G) p65 NF-κB were determined with phosphospecific antibodies. Representative results from 3 independent experiments for each stimulation are displayed. Results for Syk and PLCγ2 were quantified and analyzed for statistical significance (see Fig. S5).

Sts proteins act downstream of Dectin-1 to negatively regulate activation of the fungus-induced ROS response.

***Sts* regulates levels of Syk activation induced by *C. albicans*.** Among the first known biochemical events following Dectin-1 stimulation are upregulation of Src family member kinase activity and phosphorylation of Shp2 phosphatase (42, 43). Spleen tyrosine kinase (Syk), a nonreceptor protein kinase that is highly expressed in a variety of phagocytes, is then activated (44). We examined activation levels of Src family kinases in stimulated wild-type and *Sts*^{-/-} cells using a phosphospecific antibody. No differences were observed in the levels of Src kinase activation following stimulation of BMDCs with zymosan or wild-type *C. albicans*. (Fig. 6A). Further, no differences between stimulated wild-type and *Sts*^{-/-} cells in Shp2 phosphorylation levels were noted (Fig. 6B). In contrast, stimulation of wild-type and *Sts*^{-/-} cells with either zymosan or *C. albicans* resulted in enhanced Syk tyrosine phosphorylation in *Sts*^{-/-} cells (Fig. 6C; quantified in Fig. S5A). These observations suggest that the *Sts* phosphatases regulate Dectin-1 signaling at the level of Syk phosphorylation.

Engagement of Dectin-1 by fungus-associated ligands leads to activation of a number of intracellular signaling pathways. To investigate pathways downstream of Syk in *Sts*^{-/-} phagocytes, we examined activation of PLCγ2, a downstream substrate of Syk (40). PLCγ2 was found to be hyperphosphorylated in stimulated *Sts*^{-/-} BMDCs relative to wild-type cells (Fig. 6D; quantified in Fig. S5B). We also examined the activation of extracellular signal-regulated kinase-1/2 (ERK1/2) and phosphatidylinositol

3-kinase (PI3K), signaling molecules that play critical roles in transcriptional activation downstream of C-type lectin receptors. No differences were observed in the kinetics or extent of ERK1/2 activation (Fig. 6E), or in PI3K activation, as indicated by the kinetics and extent of Akt phosphorylation (Fig. 6F). Finally, levels of activation of p65 NF- κ B in wild-type and *Sts*^{-/-} cells following stimulation with either zymosan or *C. albicans* were identical (Fig. 6G). These results suggest that the Sts proteins could regulate a specific Syk-PLC γ 2-ROS signaling axis downstream of Dectin-1 that is independent of the pathways regulating Dectin-1/Syk-induced cytokine gene expression.

DISCUSSION

Combination therapy that pairs the use of traditional antibiotics with agents to enhance beneficial host immune responses is considered an important therapeutic goal for the treatment of intractable infections and of those for which antibiotic resistance is a looming concern (11, 12). Interestingly, genetic inactivation of the Sts proteins dramatically improves host survival following lethal doses of intravenous *C. albicans*, suggesting that they are possible targets to enhance host antifungal immunity. Importantly, the resistance of *Sts*^{-/-} mice is accompanied by rapid fungal clearance within the kidney, sharply decreased levels of inflammatory molecules, and an absence of inflammatory lesions. While our previous analysis revealed key differences in the immunological responses of wild-type versus *Sts*^{-/-} mice (16), it did not provide mechanistic insights into how Sts inactivation alters immune responses and increases protection from systemic infection. In this study, therefore, we sought to identify underlying cellular and molecular components of the enhanced antifungal immune response displayed by *Sts*^{-/-} mice.

Increased resistance to systemic *C. albicans* is mediated by *Sts*^{-/-} leukocytes. Comparative analyses of fungal clearance within infected mice provided an important clue into underlying mechanisms. Critically, *C. albicans* grew similarly in wild-type and *Sts*^{-/-} kidneys during the first 12 h postinfection. As kidney-resident phagocytes represent the primary innate immune cell population within uninfected kidneys (45), this observation suggests that the initial responses of resident phagocytes do not account for the differential abilities of wild-type and *Sts*^{-/-} mice to control the infection. However, levels of fungal CFU within infected kidneys begin to differ between 12 and 18 h postinfection (Fig. 1), with *Sts*^{-/-} CFU beginning to decline at a time when large numbers of leukocytes enter the renal compartment to counteract the infection (23, 31). This suggests that a key contribution is made by *Sts*^{-/-} bone marrow-derived leukocytes, a hypothesis that is supported by our radiation chimera studies in which animals reconstituted with *Sts*^{-/-} marrow had improved fungal clearance and enhanced survival relative to animals receiving wild-type marrow (Fig. 2). *Ex vivo* coculture analysis also demonstrated increased fungal growth suppression associated with *Sts*^{-/-} phagocytes (Fig. 3). Together, these observations suggest that the Sts phosphatases negatively regulate intrinsic antifungal responses within key leukocyte populations.

Increased ROS production downstream of Dectin-1-Syk signaling in *Sts*^{-/-} cells. After stimulating BMDCs with fungal ligands, we observed significantly heightened ROS production in *Sts*^{-/-} cells but no differences in other antifungal responses such as cytokine production or generation of nitric oxide (Fig. 4). ROS production is known to be induced following engagement of the CLR Dectin-1 (46), and we confirmed the involvement of Dectin-1 using both a competitive inhibitor and blocking antibodies. While the signaling pathway from Dectin-1 to initiation of the ROS response has not been fully elucidated, one established component is the Syk kinase (38, 44, 47). Using a phosphospecific antibody that recognizes the tyrosine phosphorylated activation loop of Syk, we observed hyperphosphorylation of Syk in *Sts*^{-/-} BMDCs following stimulation with zymosan or infection with *C. albicans* (Fig. 6). Under these conditions, there was no evidence of increased activation of upstream components such as Src kinases or Shp2. Therefore, our data suggest that Sts regulates signaling events downstream of Dectin-1 at the level of Syk phosphorylation and activation, perhaps by

direct dephosphorylation of Syk. The idea of a role for Sts in regulating Syk activity in BMDCs is supported by studies in other cell types that demonstrated that Syk is a Sts target (19, 21, 22).

Further evidence for heightened Syk kinase activity in *Sts*^{-/-} BMDCs lies in the observation that PLCγ2, a putative Syk substrate, displays increased phosphorylation following stimulation of the Dectin-1 pathway. Interestingly, we did not observe any differences in the levels of activation of the mitogen-activated protein kinase (MAPK) and PI3K pathways, two signaling pathways also thought to be downstream of Syk (48). We also observed no differences between wild-type and *Sts*^{-/-} cells in production of TNF-α, IL-6, and IL-1β, which are three cytokines that have been shown to lie downstream of the location of Syk activation (47). Together, these data highlight complexity in the regulation of Syk signaling that heretofore has not been described. In particular, the distinct effects on downstream effector pathways in *Sts*^{-/-} cells suggest that Syk-mediated activation of downstream pathway components occurs in a differentially regulated manner. Whether this involves interaction of activated Syk with multiple distinct regulatory factors or differential subcellular localization of activated Syk is currently unclear. How Sts deficiency and increased Syk activation together lead selectively to increased ROS production is currently being investigated.

Cell-specific regulation of antifungal responses by Sts. Interestingly, our *ex vivo* analysis data suggest that Sts regulates leukocytes in a cell-specific manner. In particular, while *Sts*^{-/-} BMDCs displayed increased candidacidal activity, BM-derived macrophages and BM-derived monocytes were unaffected by Sts inactivation. Furthermore, although bone marrow monocytes and neutrophils both expressed high levels of the Sts proteins, only *Sts*^{-/-} monocytes displayed enhanced *C. albicans* growth-suppressive properties. The underlying basis for a cell-specific role for Sts in regulating antifungal responses is currently unclear, but it could indicate important differences in the manner in which different innate immune cells respond to fungal pathogens. These observations are consistent with a previous report from a study demonstrating that different bone marrow-derived cell lineages exhibit differential responses to fungal ligands (49). It will be interesting to determine how the cell specificity observed *ex vivo* influences the *in vivo* immune response to fungal infection.

Increasing resistance to *C. albicans* infection. Similarly to the Sts proteins, two other gene products (Jnk1 and Cbl-b) have recently been shown to negatively regulate phagocyte signaling pathways such that the corresponding gene deletions result in mice that have increased resistance to *C. albicans* bloodstream infection (12, 50–53). Jnk1, a member of the MAPK family of enzymes, negatively regulates activation of the transcription factor NFATc1. NFATc1 induces expression of the CLR CD23, and CD23 expression is upregulated in Jnk1^{-/-} mice phagocytes, resulting in elevated levels of inducible nitric oxide synthase (iNOS) (Nos2) expression. Therefore, the protection of Jnk1^{-/-} mice from systemic candidiasis appears to stem from increased fungus-induced NO production (50). The ubiquitin ligase Cbl-b mediates Dectin-1 internalization and degradation. In its absence, Dectin-1 surface expression is stabilized, resulting in Syk hyperactivation and enhanced phagocyte antifungal responses (51–53). Interestingly, while Cbl-b^{-/-} BMDCs demonstrate increases in both ROS and cytokine production levels following infection with *C. albicans*, *Sts*^{-/-} cells display an augmented ROS response without concomitant increases in cytokine production. Nonetheless, an intriguing property common to Jnk1^{-/-}, Cbl-b^{-/-}, and *Sts*^{-/-} mutant mice is increased activation of phagocyte signaling pathways downstream of fungal CLRs, with consequent increases in antifungal effector activities. These observations offer insights into developing novel immune-enhancing therapeutics that could be paired with traditional antifungal antibiotics to ameliorate the destructive effects of systemic *C. albicans* infection.

MATERIALS AND METHODS

Mouse strains and cells. The generation of C57/B6 mice containing the Sts mutations has been previously described (17, 54, 55). Mice were housed in the Stony Brook University Animal Facility in

accordance with Division of Laboratory Animal Resources (DLAR) regulations. Animal protocols followed guidelines established within the "Guide for the Care and Use of Laboratory Animals" (8th ed.) published by the National Research Council of the National Academies. Protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Stony Brook University.

BMDCs were differentiated as previously described (32). Briefly, cells were cultured in RPMI medium containing 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 10 U/ml penicillin/streptomycin (Pen/Strep), 55 μ M β -mercaptoethanol (BME), and 20 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF). On days 3, 6, and 8, cells were provided fresh growth media. All BMDC experiments utilized nonadherent cells grown for 9 to 10 days in culture. BMDMs were cultured in DMEM containing 30% L929 cell supernatant (33), 20% FBS, and 1 mM sodium pyruvate for 4 days, after which cells were harvested, counted, and utilized as described. During the derivation of BMDMs, day 4 nonadherent cells were harvested as BM-derived monocytes (34).

For neutrophil purification, bone marrow cells were suspended in 4 ml of phosphate-buffered saline (PBS), placed on 3 ml Lymphoprep reagent (Axis-Shield, Oslo, Norway) (1.077 g/ml), and spun at 2,000 rpm. Alternatively, a murine neutrophil enrichment kit (Miltenyi) was utilized to obtain marrow neutrophils. Bone marrow monocytes were obtained with a murine monocyte isolation kit (Miltenyi) or an EasySep mouse monocyte kit (Stem Cell Technologies), according to the instructions of the manufacturers.

Reagents and antibodies. The following antibodies were purchased from Cell Signaling Technology, Inc.: pAKT S473 (9271), AKT (9272), p-ERK T202/Y204 (9106), ERK (9102), p-Syk Y525/526 (2710), p-PLC γ 2 Y759 (3874), p-Src family Y416 (2101), Src (2110), p-Shp2 Y542 (3715), Shp2 (3397), p-P65 S536 (3033), and P65 (6956). Anti-Syk (Syk01) and anti-Nos2 (5C1B52) antibodies were from BioLegend. Antibodies to PLC γ 2 (sc5283) were from Santa Cruz Biotechnology. Antibodies to Sts-1 and Sts-2 were previously described (17, 54). Dectin-1 antibody (2A11) was from Bio-Rad, and flow cytometry antibodies to CD45 (clone 30-F11), CD11b (clone M1/70), CD11c (clone N418), F4/80 (clone BM8), Ly6g (clone 1A8), Ly6c (clone AL-21), and I-A/I-E (clone M5/114.15.2) were from BioLegend. Luminol, PMA, horseradish peroxidase (HRP) type VI (P8375), and zymosan (Z4250) were from Sigma-Aldrich. Particulate β -glucan, soluble β -glucan, and depleted zymosan were obtained from InvivoGen.

Mouse infections. *Candida albicans* infections were carried out as previously described (16). Cells were harvested, washed twice in PBS, and counted, and cell counts were confirmed by plating dilutions onto yeast extract-peptone-dextrose (YPD) plates. Female mice were inoculated with 2.5×10^5 CFU via the lateral tail vein and monitored for 28 days. For clodronate depletion experiments, mice were administered by intravenous (i.v.) injection 1 mg clodronate/liposome formulation or control liposomes (Encapsula Nano Sciences, Brentwood, TN) 24 h prior to inoculation with *C. albicans* (1×10^5 CFU) (26). To obtain kidney CFU, kidneys were excised at the indicated times postinfection, placed in 5 ml PBS, and homogenized. The number of CFU per gram of tissue was determined by plating homogenate serial dilutions onto YPD medium plates and incubating at 30°C.

Derivation and use of radiation chimeras. Female mice (8 to 10 weeks of age) were dosed with 1,100 rads from a gamma cell irradiator (GammaCell 40; AEC Ltd.) and administered 8×10^6 bone marrow cells via tail vein injection within 1 h. Chimeric mice were housed for 12 weeks and then utilized for survival or organ CFU assays. Graphing and statistical analysis of survival after infection were carried out using a log rank test (Mantel-Haenszel test) with SigmaPlot software (SigmaPlot Systat Software, Inc., San Jose, CA).

Ex vivo *C. albicans* coculture assay. Nonfilamentous *C. albicans* mutant *cph1 Δ efg1 Δ* cells (28) were grown overnight, reinoculated into fresh medium, and grown to an optical density at 600 nm (OD₆₀₀) of 0.7 to 0.9. Cells were washed twice in PBS and cocultured with cells obtained from male or female mice in RPMI media at a multiplicity of infection (MOI) of 0.0375 to 0.125, with or without 10 ng/ml PMA, for 24 h in a 96-well plate. Wells were washed once with water and collected in 1 ml of deionized water to lyse nonfungal cells. Fungal CFU were obtained by plating serial dilutions onto YPD plates.

Pathway analysis. Cells obtained from male or female mice were stimulated, washed, and lysed in buffer containing 0.05 M Tris, 0.15 M sodium chloride, 5 μ M EDTA, 0.2 mM pervanadate, 0.5 mg/ml phenylmethylsulfonyl fluoride (PMSF), and 1 \times Roche protease inhibitors. Lysates were clarified by centrifugation, subjected to SDS-PAGE, and transferred to nitrocellulose (Whatman). Membranes were probed with specific antibody and the appropriate secondary antibody and were developed with an Odyssey CLx imaging system (Li-COR). Immunoprecipitations were conducted by rotating lysates with specific antibody for 2 h at 4°C, followed by 1 h at 4°C with protein A Sepharose beads (Sigma). Beads were washed three times in lysis buffer, and proteins were eluted with 2 \times Laemmli sample buffer and separated by SDS-PAGE. Dectin-1 downregulation was evaluated using a FACScan cytometer (Cytex Biosciences).

Measurement of ROS and NO production. Levels of reactive oxygen species were measured as previously described (56). Briefly, BMDCs (1×10^5 cells/well) or neutrophils (4×10^5 cells/well) were plated in triplicate wells of a 96-well plate. Stimuli were prepared in RPMI media containing 600 μ M luminol and 16 units of HRP/ml. Reagent medium (100 μ l) was added to 100 μ l of preplated cells, and luminescence was measured at regular intervals on a Filtermax F5 96-well plate reader using Softmax Pro software (Molecular Devices, Sunnyvale, CA). Griess reagent was used to evaluate levels of NO₂ production in cell culture supernatants per the instructions of the manufacturer (Promega).

Cytokine measurements. Cells were placed in a 6-well tissue culture plate and stimulated with zymosan (100 μ g/ml) or heat-killed SC5314 (MOI of 2). The supernatant was collected and frozen at -80°C until measured. IL-6, TNF- α (BioLegend), and IL-1 β (Thermo Fisher Invitrogen) levels were measured by enzyme-linked immunosorbent assay (ELISA) according to provided instructions.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.00782-18>.

FIG S1, TIF file, 1.9 MB.

FIG S2, TIF file, 0.8 MB.

FIG S3, TIF file, 1.5 MB.

FIG S4, TIF file, 0.4 MB.

FIG S5, TIF file, 0.9 MB.

ACKNOWLEDGMENTS

We thank Laurie Levine, Jean Rooney, and other staff members of the Stony Brook DLAR for help with animal studies. We also acknowledge the technical support provided by Todd Rueb and Rebecca Connor of the Stony Brook University Flow Cytometry Core for help with fluorescence-activated cell sorting. We thank Michael Hayman and members of the laboratories of N.C. and J.B.K. for discussions.

This work was supported by grants to N.C. from Stony Brook University; the Stony Brook Medical Center Dean's Office; the National Heart, Lung, and Blood Institute (NIH) under award U01HL127522 (Clinton Rubin, principal investigator [PI]); and the Office of the Assistant Secretary of Defense for Health Affairs through Peer-Reviewed Medical Research Program W81XWH-16-PRMRP-DA (PR161377) and by funds from the National Institutes of Health awarded to N.C. (R21 AI130859) and J.K. (R01 AI047837). G.L.R. thanks the Fullbright Research Scholar Program (United States-Italy) and the **Short Term Mobility Program of the National Research Council (Italy)** for support. The funders had no role in the study design, data collection and interpretation, or the decision to submit work for publication.

We declare that we have no financial conflict of interest.

REFERENCES

- Brown GD, Denning DW, Levitz SM. 2012. Tackling human fungal infections. *Science* 336:647. <https://doi.org/10.1126/science.1222236>.
- Lionakis MS, Iliev ID, Hohl TM. 2017. Immunity against fungi. *JCI Insight* 2:e93156. <https://doi.org/10.1172/jci.insight.93156>.
- Lionakis MS. 2014. New insights into innate immune control of systemic candidiasis. *Med Mycol* 52:555–564. <https://doi.org/10.1093/mmy/myu029>.
- Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. *Crit Rev Microbiol* 36:1–53. <https://doi.org/10.3109/10408410903241444>.
- Perlin DS. 2009. Antifungal drug resistance: do molecular methods provide a way forward? *Curr Opin Infect Dis* 22:568–573. <https://doi.org/10.1097/QCO.0b013e3283321ce5>.
- Kullberg BJ, Arendrup MC. 2015. Invasive candidiasis. *N Engl J Med* 373:1445–1456. <https://doi.org/10.1056/NEJMra1315399>.
- Spampinato C, Leonardi D. 2013. *Candida* infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. *BioMed Res Int* 2013:204237. <https://doi.org/10.1155/2013/204237>.
- CDC. 2013. Antibiotic resistance threats in the United States, 2013. <http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>.
- Romani L. 2011. Immunity to fungal infections. *Nat Rev Immunol* 11: 275–288. <https://doi.org/10.1038/nri2939>.
- Erwig LP, Gow NA. 2016. Interactions of fungal pathogens with phagocytes. *Nat Rev Microbiol* 14:163–176. <https://doi.org/10.1038/nrmicro.2015.21>.
- Duggan S, Leonhardt I, Hünig K, Kurzai O. 2015. Host response to *Candida albicans* bloodstream infection and sepsis. *Virulence* 6:316–326. <https://doi.org/10.4161/21505594.2014.988096>.
- Carpino N, Naseem S, Frank DM, Konopka JB. 2017. Modulating host signaling pathways to promote resistance to infection by *Candida albicans*. *Front Cell Infect Microbiol* 7:481. <https://doi.org/10.3389/fcimb.2017.00481>.
- Spellberg B, Ibrahim AS, Edwards JE, Jr, Filler SG. 2005. Mice with disseminated candidiasis die of progressive sepsis. *J Infect Dis* 192: 336–343. <https://doi.org/10.1086/430952>.
- Zwolaneck F, Riedelberger M, Stolz V, Jenull S, Istel F, Köprülü AD, Ellmeier W, Kuchler K. 2014. The non-receptor tyrosine kinase Tec controls assembly and activity of the noncanonical caspase-8 inflammasome. *PLoS Pathog* 10:e1004525. <https://doi.org/10.1371/journal.ppat.1004525>.
- Lionakis MS, Fischer BG, Lim JK, Swamydas M, Wan W, Richard Lee CCR, Cohen JL, Scheinberg P, Gao JL, Murphy PM. 2012. Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. *PLoS Pathog* 8:e1002865. <https://doi.org/10.1371/journal.ppat.1002865>.
- Naseem S, Frank D, Konopka JB, Carpino N. 2015. Protection from systemic *Candida albicans* infection by inactivation of the Sts phosphatases. *Infect Immun* 83:637–645. <https://doi.org/10.1128/IAI.02789-14>.
- Carpino N, Turner S, Mekala D, Takahashi Y, Zang H, Geiger TL, Doherty P, Ihle JN. 2004. Regulation of ZAP-70 activation and TCR signaling by two related proteins, Sts-1 and Sts-2. *Immunity* 20:37–46. [https://doi.org/10.1016/S1074-7613\(03\)00351-0](https://doi.org/10.1016/S1074-7613(03)00351-0).
- Newman TN, Liverani E, Ivanova E, Russo GL, Carpino N, Ganea D, Safadi F, Kunapuli SP, Tsygankov AY. 2014. Members of the novel UBASH3/STS/TULA family of cellular regulators suppress T-cell-driven inflammatory responses in vivo. *Immunol Cell Biol* 92:837–850. <https://doi.org/10.1038/icb.2014.60>.
- Tsygankov AY. 2013. Tula-family proteins: a new class of cellular regulators. *J Cell Physiol* 228:43–49. <https://doi.org/10.1002/jcp.24128>.
- Mikhailik A, Ford B, Keller J, Chen Y, Nassar N, Carpino N. 2007. A phosphatase activity of Sts-1 contributes to the suppression of TCR signaling. *Mol Cell* 27:486–497. <https://doi.org/10.1016/j.molcel.2007.06.015>.
- Reppschläger K, Gosselin J, Dangelmaier CA, Thomas DH, Carpino N, McKenzie SE, Kunapuli SP, Tsygankov AY. 2016. TULA-2 protein phosphatase suppresses activation of Syk through the GPVI platelet receptor for collagen by dephosphorylating Tyr(P)-346, a regulatory site of Syk. *J Biol Chem* 291:22427–22441. <https://doi.org/10.1074/jbc.M116.743732>.
- de Castro RO, Zhang J, Groves JR, Barbu EA, Siraganian RP. 2012. Once phosphorylated, tyrosines in the carboxyl terminus of protein-tyrosine kinase Syk interact with signaling proteins, including TULA-2, a negative regulator of mast cell degranulation. *J Biol Chem* 287:8194–8204. <https://doi.org/10.1074/jbc.M111.326850>.

23. Lionakis MS, Lim JK, Lee CC, Murphy PM. 2011. Organ-specific innate immune responses in a mouse model of invasive candidiasis. *J Innate Immun* 3:180–199. <https://doi.org/10.1159/000321157>.
24. Lionakis MS, Swamydas M, Fischer BG, Plantinga TS, Johnson MD, Jaeger M, Green NM, Masedunskas A, Weigert R, Mikelis C, Wan W, Lee CCR, Lim JK, Rivollier A, Yang JC, Laird GM, Wheeler RT, Alexander BD, Perfect JR, Gao JL, Kullberg BJ, Netea MG, Murphy PM. 2013. CX3CR1-dependent renal macrophage survival promotes *Candida* control and host survival. *J Clin Invest* 123:5035–5051. <https://doi.org/10.1172/JCI71307>.
25. Xu W, Solis NV, Ehrlich RL, Woolford CA, Filler SG, Mitchell AP. 2015. Activation and alliance of regulatory pathways in *C. albicans* during mammalian infection. *PLoS Biol* 13:e1002076. <https://doi.org/10.1371/journal.pbio.1002076>.
26. Qian Q, Jutila MA, Van Rooijen N, Cutler JE. 1994. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. *J Immunol* 152:5000–5008.
27. Marciel A, Harscus D, Thomas DY, Whiteway M. 2002. *Candida albicans* killing by RAW 264.7 mouse macrophage cells: effects of *Candida* genotype, infection ratios, and gamma interferon treatment. *Infect Immun* 70:6319–6329. <https://doi.org/10.1128/IAI.70.11.6319-6329.2002>.
28. Lo HJ, Köhler JR, DiDomenico B, Loeberberg D, Cacciapuoti A, Fink GR. 1997. Nonfilamentous *C. albicans* mutants are avirulent. *Cell* 90:939–949. [https://doi.org/10.1016/S0092-8674\(00\)80358-X](https://doi.org/10.1016/S0092-8674(00)80358-X).
29. Domínguez-Andrés J, Feo-Lucas L, Minguito de la Escalera M, González L, López-Bravo M, Ardavin C. 2017. Inflammatory Ly6C^{high} monocytes protect against candidiasis through IL-15-driven NK cell/neutrophil activation. *Immunity* 46:1059–1072.e4. <https://doi.org/10.1016/j.immuni.2017.05.009>.
30. Swamydas M, Gao JL, Break TJ, Johnson MD, Jaeger M, Rodriguez CA, Lim JK, Green NM, Collar AL, Fischer BG, Lee CCR, Perfect JR, Alexander BD, Kullberg BJ, Netea MG, Murphy PM, Lionakis MS. 2016. CXCR1-mediated neutrophil degranulation and fungal killing promote *Candida* clearance and host survival. *Sci Transl Med* 8:322ra10. <https://doi.org/10.1126/scitranslmed.aac7718>.
31. Ngo LY, Kasahara S, Kumasaka DK, Knoblaugh SE, Jhingran A, Hohl TM. 2014. Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis. *J Infect Dis* 209:109–119. <https://doi.org/10.1093/infdis/jit413>.
32. Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F, Romani N, Schuler G. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. *J Immunol Methods* 223:77–92. [https://doi.org/10.1016/S0022-1759\(98\)00204-X](https://doi.org/10.1016/S0022-1759(98)00204-X).
33. Doyle CR, Pan JA, Mena P, Zong WX, Thanassi DG. 2014. TolC-dependent modulation of host cell death by the Francisella tularensis live vaccine strain. *Infect Immun* 82:2068–2078. <https://doi.org/10.1128/IAI.00044-14>.
34. Francke A, Herold J, Weinert S, Strasser RH, Braun-Dullaeus RC. 2011. Generation of mature murine monocytes from heterogeneous bone marrow and description of their properties. *J Histochem Cytochem* 59:813–825. <https://doi.org/10.1369/0022155411416007>.
35. Sancho D, Reis e Sousa C. 2012. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. *Annu Rev Immunol* 30:491–529. <https://doi.org/10.1146/annurev-immunol-031210-101352>.
36. Drummond RA, Brown GD. 2013. Signalling C-type lectins in antimicrobial immunity. *PLoS Pathog* 9:e1003417. <https://doi.org/10.1371/journal.ppat.1003417>.
37. Brown GD. 2011. Innate antifungal immunity: the key role of phagocytes. *Annu Rev Immunol* 29:1–21. <https://doi.org/10.1146/annurev-immunol-030409-101229>.
38. Gross O, Poock H, Bscheider M, Dostert C, Hanneschläger N, Endres S, Hartmann G, Tardivel A, Schweighoffer E, Tybulewicz V, Mocsai A, Tschoop J, Ruland J. 2009. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. *Nature* 459:433–436. <https://doi.org/10.1038/nature07965>.
39. Reid DM, Gow NA, Brown GD. 2009. Pattern recognition: recent insights from Dectin-1. *Curr Opin Immunol* 21:30–37. <https://doi.org/10.1016/j.coi.2009.01.003>.
40. Plato A, Willment JA, Brown GD. 2013. C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. *Int Rev Immunol* 32:134–156. <https://doi.org/10.3109/08830185.2013.777065>.
41. Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan ASH, Magee AS, Danielson ME, Weiss A, Vasilakos JP, Underhill DM. 2011. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. *Nature* 472:471–475. <https://doi.org/10.1038/nature10071>.
42. Page TH, Smolinska M, Gillespie J, Urbaniak AM, Foxwell BM. 2009. Tyrosine kinases and inflammatory signalling. *Curr Mol Med* 9:69–85. <https://doi.org/10.2174/156652409787314507>.
43. Deng Z, Ma S, Zhou H, Zang A, Fang Y, Li T, Shi H, Liu M, Du M, Taylor PR, Zhu HH, Chen J, Meng G, Li F, Chen C, Zhang Y, Jia XM, Lin X, Zhang X, Pearlman E, Li X, Feng GS, Xiao H. 2015. Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses. *Nat Immunol* 16:642–652. <https://doi.org/10.1038/ni.3155>.
44. Kerrigan AM, Brown GD. 2011. Syk-coupled C-type lectins in immunity. *Trends Immunol* 32:151–156. <https://doi.org/10.1016/j.it.2011.01.002>.
45. Nelson PJ, Rees AJ, Griffin MD, Hughes J, Kurts C, Duffield J. 2012. The renal mononuclear phagocytic system. *J Am Soc Nephrol* 23:194–203. <https://doi.org/10.1681/ASN.2011070680>.
46. Underhill DM, Rossnagle E, Lowell CA, Simmons RM. 2005. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. *Blood* 106:2543–2550. <https://doi.org/10.1182/blood-2005-03-1239>.
47. Poock H, Ruland J. 2010. SYK kinase signaling and the NLRP3 inflammasome in antifungal immunity. *J Mol Med* 88:745–752. <https://doi.org/10.1007/s00109-010-0631-4>.
48. Blanco-Menéndez N, Del Fresno C, Fernandes S, Calvo E, Conde-Garrosa R, Kerr WG, Sancho D. 2015. SHIP-1 couples to the Dectin-1 hemITAM and selectively modulates reactive oxygen species production in dendritic cells in response to *Candida albicans*. *J Immunol* 195:4466–4478. <https://doi.org/10.4049/jimmunol.1402874>.
49. Goodridge HS, Shimada T, Wolf AJ, Hsu YM, Becker CA, Lin X, Underhill DM. 2009. Differential use of CARD9 by dectin-1 in macrophages and dendritic cells. *J Immunol* 182:1146–1154. <https://doi.org/10.4049/jimmunol.182.2.1146>.
50. Zhao X, Guo Y, Jiang C, Chang Q, Zhang S, Luo T, Zhang B, Jia X, Hung MC, Dong C, Lin X. 2017. JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression. *Nat Med* 23:337–346. <https://doi.org/10.1038/nm.4260>.
51. Wirnsberger G, Zvolanek F, Asaoka T, Koziereadzi I, Tortola L, Wimmer RA, Kavirayani A, Fresser F, Baier G, Langdon WY, Ikeda F, Kuchler K, Penninger JM. 2016. Inhibition of CBLB protects from lethal *Candida albicans* sepsis. *Nat Med* 22:915–923. <https://doi.org/10.1038/nm.4134>.
52. Xiao Y, Tang J, Guo H, Zhao Y, Tang R, Ouyang S, Zeng Q, Rappleye CA, Rajaram MVS, Schlesinger LS, Tao L, Brown GD, Langdon WY, Li BT, Zhang J. 2016. Targeting CBLB as a potential therapeutic approach for disseminated candidiasis. *Nat Med* 22:906–914. <https://doi.org/10.1038/nm.4141>.
53. Zhu LL, Luo TM, Xu X, Guo YH, Zhao XQ, Wang TT, Tang B, Jiang YY, Xu JF, Lin X, Jia XM. 2016. E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity. *J Exp Med* 213:1555–1570. <https://doi.org/10.1084/jem.20151932>.
54. Carpino N, Kobayashi R, Zang H, Takahashi Y, Jou ST, Feng J, Nakajima H, Ihle JN. 2002. Identification, cDNA cloning, and targeted deletion of p70, a novel, ubiquitously expressed SH3 domain-containing protein. *Mol Cell Biol* 22:7491–7500. <https://doi.org/10.1128/MCB.22.21.7491-7500.2002>.
55. San Luis B, Sondgeroth B, Nassar N, Carpino N. 2011. Sts-2 is a phosphatase that negatively regulates zeta-associated protein (ZAP)-70 and T cell receptor signaling pathways. *J Biol Chem* 286:15943–15954. <https://doi.org/10.1074/jbc.M110.177634>.
56. Frohner IE, Bourgeois C, Yatsyk K, Majer O, Kuchler K. 2009. *Candida albicans* cell surface superoxide dismutases degrade host-derived reactive oxygen species to escape innate immune surveillance. *Mol Microbiol* 71:240–252. <https://doi.org/10.1111/j.1365-2958.2008.06528.x>.